In the first quarter, Johnson & Johnson’s (JNJ) Pharmaceutical segment reported 7.9% YoY (year-over-year) growth in worldwide revenue on an operational basis, better than the overall market’s growth. The segment reported 4.3% YoY sales growth in the US market on both a reported and an operational basis. It reported YoY rises of 3.9% on a reported basis and 12.2% on an operational basis in revenues earned from international markets.
In the first quarter, Johnson & Johnson’s Pharmaceuticals segment reported a 7.9% YoY rise in worldwide sales, a 4.3% YoY rise in US market sales, and a 12.2% YoY rise in ex-US market sales on an adjusted operational basis.
Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
According to Johnson & Johnson’s first-quarter earnings conference call, its worldwide revenues were affected favorably by 200 basis points due to its earlier pricing adjustments for Stelara, Invokana, and Remicade. However, these pricing adjustments coupled with generic erosion for Zytiga negatively affected the company’s US market growth in the first quarter.
In the first quarter, Johnson & Johnson’s oncology portfolio reported revenue of $2.52 billion, reflecting YoY rises of 9.0% on a reported basis and 14.5% on an operational basis.
In the first quarter, Darzalex was a major revenue driver for the company, reporting a 51% YoY rise in worldwide sales and a 33% YoY rise in US market sales. According to the company’s first-quarter earnings conference call, the drug reported a four-percentage-point increase in its share in the US market due to its strong uptake across all lines of therapy. In international markets, Darzalex reported an 18% YoY rise in revenue due to the rising penetration and increasing market share of the drug in the Asia-Pacific, Latin America, and Europe, the Middle East, and Africa. In the first quarter, Johnson & Johnson launched Darzalex in nine new markets.
In the first quarter, Johnson & Johnson reported submission of applications to the FDA seeking approval for Darzalex in a combination regimen in first-line, transplant-eligible multiple myeloma and first-line, transplant-ineligible multiple myeloma indications. The drug also secured FDA approval for its split-dosing regimen in the quarter.